Sanofi, Regeneron’s Dupixent Meets Late-Stage Urticaria Study Goals
ZacksThis is the second pivotal late-stage study on SNY/REGN’s Dupixent in chronic spontaneous urticaria indication to meet primary and key secondary endpoints.
This is the second pivotal late-stage study on SNY/REGN’s Dupixent in chronic spontaneous urticaria indication to meet primary and key secondary endpoints.